These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 11571337)

  • 1. Serum IFN neutralizing antibodies and neopterin levels in a cross-section of MS patients.
    Cook SD; Quinless JR; Jotkowitz A; Beaton P;
    Neurology; 2001 Sep; 57(6):1080-4. PubMed ID: 11571337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eight-year immunogenicity and safety of interferon beta-1a-Avonex treatment in patients with multiple sclerosis.
    Herndon RM; Rudick RA; Munschauer FE; Mass MK; Salazar AM; Coats ME; Labutta R; Richert JR; Cohan SL; Genain C; Goodkin D; Toal M; Riester K
    Mult Scler; 2005 Aug; 11(4):409-19. PubMed ID: 16042223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequency and magnitude of interferon β neutralizing antibodies in the evaluation of interferon β immunogenicity in patients with multiple sclerosis.
    Grossberg SE; Oger J; Grossberg LD; Gehchan A; Klein JP
    J Interferon Cytokine Res; 2011 Mar; 31(3):337-44. PubMed ID: 21226608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory.
    Bertolotto A; Malucchi S; Sala A; Orefice G; Carrieri PB; Capobianco M; Milano E; Melis F; Giordana MT
    J Neurol Neurosurg Psychiatry; 2002 Aug; 73(2):148-53. PubMed ID: 12122172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biologic impact of interferon antibodies, and complexities in assessing their clinical significance.
    Rudick RA
    Neurology; 2003 Nov; 61(9 Suppl 5):S31-4. PubMed ID: 14610110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients.
    Bertolotto A; Gilli F; Sala A; Capobianco M; Malucchi S; Milano E; Melis F; Marnetto F; Lindberg RL; Bottero R; Di Sapio A; Giordana MT
    Neurology; 2003 Feb; 60(4):634-9. PubMed ID: 12601105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determination of interferon beta neutralizing antibodies in multiple sclerosis: improvement of clinical sensitivity of a cytopathic effect assay.
    Massart C; Gibassier J; de Seze J; Debouverie M; Moreau T; Pelletier J; Vermersch P; Edan G
    Clin Chim Acta; 2008 May; 391(1-2):98-101. PubMed ID: 18249193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG).
    Rudick RA; Simonian NA; Alam JA; Campion M; Scaramucci JO; Jones W; Coats ME; Goodkin DE; Weinstock-Guttman B; Herndon RM; Mass MK; Richert JR; Salazar AM; Munschauer FE; Cookfair DL; Simon JH; Jacobs LD
    Neurology; 1998 May; 50(5):1266-72. PubMed ID: 9595973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neutralizing antibodies to interferon beta-1a and interferon beta-1b in MS patients are cross-reactive.
    Khan OA; Dhib-Jalbut SS
    Neurology; 1998 Dec; 51(6):1698-702. PubMed ID: 9855525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
    Goodin DS; Frohman EM; Hurwitz B; O'Connor PW; Oger JJ; Reder AT; Stevens JC
    Neurology; 2007 Mar; 68(13):977-84. PubMed ID: 17389300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differing immunogenic potentials of interferon beta preparations in multiple sclerosis patients.
    Gneiss C; Tripp P; Reichartseder F; Egg R; Ehling R; Lutterotti A; Khalil M; Kuenz B; Mayringer I; Reindl M; Berger T; Deisenhammer F
    Mult Scler; 2006 Dec; 12(6):731-7. PubMed ID: 17263000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacodynamics of interferon beta in multiple sclerosis patients with or without serum neutralizing antibodies.
    Scagnolari C; Duda P; Bagnato F; De Vito G; Alberelli A; Lavolpe V; Girardi E; Durastanti V; Trojano M; Kappos L; Antonelli G
    J Neurol; 2007 May; 254(5):597-604. PubMed ID: 17420930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies.
    Deisenhammer F; Reindl M; Harvey J; Gasse T; Dilitz E; Berger T
    Neurology; 1999 Apr; 52(6):1239-43. PubMed ID: 10214750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferon beta neutralizing antibodies in multiple sclerosis: neutralizing activity and cross-reactivity with three different preparations.
    Bertolotto A; Malucchi S; Milano E; Castello A; Capobianco M; Mutani R
    Immunopharmacology; 2000 Jul; 48(2):95-100. PubMed ID: 10936507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multicenter, open-label, phase II study of the immunogenicity and safety of a new prefilled syringe (liquid) formulation of Avonex in patients with multiple sclerosis.
    Phillips JT; Rice G; Frohman E; Vande Gaer L; Scott T; Haas J; Eggenberger E; Freedman MS; Stuart W; Cunha L; Jacobs L; Oger J; Arnold D; Murray TJ; DiBiase M; Jethwa V; Goelz S
    Clin Ther; 2004 Apr; 26(4):511-21. PubMed ID: 15189748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutralizing antibodies reduce MxA protein induction in interferon-beta-1a-treated MS patients.
    Vallittu AM; Halminen M; Peltoniemi J; Ilonen J; Julkunen I; Salmi A; Erälinna JP;
    Neurology; 2002 Jun; 58(12):1786-90. PubMed ID: 12084878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study.
    Kappos L; Clanet M; Sandberg-Wollheim M; Radue EW; Hartung HP; Hohlfeld R; Xu J; Bennett D; Sandrock A; Goelz S;
    Neurology; 2005 Jul; 65(1):40-7. PubMed ID: 16009883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutralizing antibodies to multiple sclerosis treatments.
    Rossman HS
    J Manag Care Pharm; 2004 Jun; 10(3 Suppl B):S12-9. PubMed ID: 15253685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of neutralizing antibodies on biomarker responses to interferon beta: the INSIGHT study.
    Pachner AR; Warth JD; Pace A; Goelz S;
    Neurology; 2009 Nov; 73(18):1493-500. PubMed ID: 19884577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Persistency of neutralizing antibodies depends on titer and interferon-beta preparation.
    Hegen H; Schleiser M; Gneiss C; Di Pauli F; Ehling R; Kuenz B; Lutterotti A; Berger T; Deisenhammer F
    Mult Scler; 2012 May; 18(5):610-5. PubMed ID: 22013146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.